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question of the genetic risks to the offspring of CHD patients. 
As a result, there is an increasing need for the incorporation of 
medical genetics in CHD management, with possible impli-
cations on diagnosis, recurrence risk, and family screening.(7)
Despite many advances in diagnosis and treatment of CHD, 
our understanding of its causes remains relatively poor, though 
the role of genetic mutations and chromosomal rearrangement 
has been demonstrated.(8) Sporadic, non-syndromic CHD is a 
complex genetic disorder with evidence for polygenic sus-
ceptibility constituted by an observed elevated recurrence risk 
amongst first-degree relatives, albeit without Mendelian segre-
gation.(5,9) In families with an index case with CHD, the risk of 
the same CHD phenotype amongst siblings increases between 
3-fold and 80-fold depending on the type of CHD, while the 
risk of another CHD phenotype increases 2- to 3-fold.(5) 
Advanced genetic approaches including whole-exome se-
quencing (WES) and chromosomal microarrays (CMAs) have 
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Congenital heart disease (CHD; Table I) is the most prevalent 
birth defect and the leading non-infectious cause of paediatric 
morbidity and mortality worldwide.(1,2) Approximately 9 per 
1 000 children are born with CHD annually,(3) with an esti-
mated 11 000 South African children born with this condition 
each year.(4) CHD is defined as a structural malformation of 
the heart and/or great blood vessels that occurs before 
birth.(3) The disease develops as a result of perturbations in 
normal cardiac development,(5) and can range from asympto-
matic to life-threatening depending on the severity and com-
plexity of the cardiac lesion(s). Tremendous strides in treat-
ment, management, and cardiothoracic surgery have led to an 
increased survival rate of children born with CHD, and con-
sequently a growing adult CHD population.(6) This poses the 
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sification systems based on anatomical, functional, and clinical 
features.(14-17) The wide range of cardiac lesions and underlying 
developmental mechanisms has made aetiological and epidemi-
ological studies of CHD a great challenge. However, CHDs 
may be divided into two simple categories: isolated CHD, in 
which the congenital defect is limited to the heart, and CHD 
with extracardiac anomalies (ECAs), in which additional fea-
tures of other body systems, such as neurodevelopmental 
delay, craniofacial and limb malformations, are observed, some-
times forming part of a syndrome. 
BURDEN OF DISEASE
Cardiovascular disease (CVD) is the leading cause of death 
worldwide,(18) an increasingly important healthcare concern due 
to the widespread effect of urbanisation seen in low- and 
lower-middle-income countries (LMICs) over the past cen-
tury.(19,20) CHD is a major cause of cardiovascular morbidity and 
mortality in children and a significant health burden world-
wide.(21) A systematic literature review by Liu, et al.(3) reported 
a substantial increase in CHD birth prevalence from ~4 per 
1 000 live births in 1970 to the estimated 9 per 1 000 live 
births seen today, largely due to improved screening and diag-
nosis of minor defects.(3)
Despite the significant burden of CHD, the prognosis for 
children born with CHD in higher-income countries has dras-
tically improved over the last 50 years, with over 90% of 
affected individuals surviving to adulthood.(22) This improved 
outlook can be attributed to the increased availability of pre-
natal echocardiography and improved medical and surgical 
care.(3) With the increased prevalence of CHD, the issues of 
long-term prognosis, and the underlying causes of CHD are 
gaining more global attention.(6)
The socio-economic burden of CVD including CHD falls 
heavily on LMICs, many of which are situated in sub-Saharan 
Africa (SSA).(18,23,24) The majority of children with CHD are 
born in these countries and face a starkly different prognosis 
to children with CHD in higher-income countries.(22) These 
regional differences can be attributed to limited availability of 
antenatal screening leading to fewer diagnoses and increased 
mortality rates, inadequate access to life-saving surgeries, inter-
vention, and cardiac care, and an insufficient health infrastruc-
ture.(22,25) Paediatric cardiac services are an extremely expensive 
area of medicine and are not readily available to the majority of 
patients living in SSA. The estimated CHD prevalence of 9 
per 1 000 live births is generally accepted worldwide, with 
genetic, environmental, and epigenetic factors accounting for 
the variation seen between regions.(26) However, a recent sys-
tematic review reported a signif icantly lower prevalence rate 
led to the identification of numerous rare and newly occurring 
single nucleotide variants (SNVs) and copy number variants 
(CNVs) associated with CHD.(9,10,11) Because patients with con-
firmed genetic syndromes are at higher risk of operative mor-
tality and morbidity, advancing our understanding of the 
causes of CHD will help define disease risk, improve the way 
we assess and treat individuals with CHD, and facilitate pre-
vention.(12) This review will summarise the current knowledge 
of the genetics of CHD, with specific consideration to ongoing 
research and challenges in Africa.
CONGENITAL HEART DEFECTS
The heart is the f irst organ to develop in the human embryo 
through a complex series of events reviewed in more detail 
elsewhere.(13) Any disruption during cardiogenesis can result in 
a cardiac defect. 
CHD is an umbrella term for a spectrum of cardiac anomalies 
of differing incidence and severity. The diversity of cardiac 
phenotypes implicated in CHD has resulted in multiple clas-
TABLE I: Abbreviations and acronyms.
Abbreviation Meaning
ASD Atrial septal defect
CGH Comparative genomic hybridisation
CHD Congenital heart disease
CMA Chromosomal microarray analysis
CNV Copy number variant
CVD Cardiovascular disease
ECA Extracardiac anomaly
FISH Fluorescence in situ hybridisation
LMIC Low and lower-middle-income country
MLPA Multiplex ligation-dependent probe amplifi cation
NAHR Nonallelic homologous recombination
PDA Patent ductus arteriosus
SNP Single nucleotide polymorphism
SNV Single nucleotide variant
SSA Sub-Saharan Africa
T21 Trisomy 21
TOF Tetralogy of Fallot
TS Turner syndrome
WES Whole-exome sequencing
VSD Ventricular septal defect
138
GENETICS OF CONGENITAL HEART DISEASE
in Africa (2.315 per 1 000 live births), reflecting severe re-
source constraints and limited access to healthcare, leading to 
a low detection rate and a paucity of available estimates 
from Africa.(3)
Although epidemiological data in SSA are limited, single-centre 
reports and prevalence studies amongst neonates and school 
children describe similar patterns in CHD in the region, with 
septal defects comprising the most common CHDs, followed 
by patent ductus arteriosus (PDA), and cyanotic defects such as 
Tetralogy of Fallot (TOF) and truncus arteriosus occurring less 
frequently.(27-31) In all cases, TOF appears the most common 
cyanotic form of CHD (6% - 13%). These patterns have held in 
diverse countries across SSA, such as Botswana, Uganda, 
Nigeria and Tanzania, although a 10-year cross-sectional study 
in Cameroon reported pulmonary stenosis as the second most 
common CHD in their population.(32) A recent meta-analysis 
of studies from East Africa concluded that the prevalence of 
septal defects in the region remains lower than in global meta-
analyses, but still worryingly high.(33) The estimated birth pre-
valence of CHD in Botswana was 2.8 - 4.95 per 1 000,(27) while 
prevalence amongst Nigerian school children was 6.6 per 
1 000.(34) However, a recent study of 3 857 Nigerian neo-
nates reported a high CHD prevalence of 28.8 per 1 000,(35) 
with severe CHD occurring in 3.4 per 1 000 births. These vastly 
differing results support the suggestion that the low preva-
lence of CHD in Africa (2.315 per 1 000) is likely due to a 
paucity of data from the region. 
THE AETIOLOGY OF CONGENITAL 
HEART DISEASE
The aetiology of CHD has been the focus of numerous studies 
over the past decades.(1,36-38) Although our understanding of 
the molecular pathways involved in heart development has 
improved greatly, the underlying causes of most CHD cases 
remain unclear.(39-41) Approximately 40% of CHDs are due to 
known genetic causes (aneuploidy: ~23%; de novo CNVs: 
~15%; de novo mutations: ~10%; inherited mutations: ~1%), 
but the relative contributions of epigenetic and environmental 
factors have not been quantified. It has long been appreciated 
that environmental, heritable genetic, and epigenetic factors can 
cause CHD, often in the context of a multifactorial disease.(1) 
The interaction between these risk factors is thought to increase 
susceptibility to the development of a heart defect.(12) With 
more children born with CHD surviving to adulthood and 
starting families of their own, improving our understanding of 
disease aetiology and recurrence risks has become critical. 
Importantly, understanding the causes of CHD will help clini-
cians determine the prognostic outcome for surgery or treat-
ments, and identify patients at higher risk of operative morbi-
dity and mortality.(40)
ENVIRONMENTAL RISK FACTORS FOR 
CONGENITAL HEART DISEASE
Environmental risk factors for CHD include any non-genetic 
factors that have been associated with the risk of developing a 
cardiac defect, many of which occur in utero.(40) Environmental 
factors that have been associated with CHD include maternal 
exposure to cigarette smoke, alcohol, thalidomide, isotretinoin 
and antiseizure medication,(38) infectious agents such as 
rubella,(42) and teratogens such as dioxins and pesticides.(43) 
However, the contribution of specific environmental factors to 
CHD is unknown as most associations have been derived from 
small observational studies which have not been replicated and 
may have been influenced by recall bias. Novel non-genetic 
causes and risk factors for CHD are continuously arising des-
pite efforts to minimise these modifiable influences.(44)
Certain potentially modif iable risk factors for CHD such as 
folate deficiencies and air pollution are likely to significantly af-
fect patients in LMICs, including South Africa, where exposure 
to these risk factors is at higher levels when compared to high-
income countries. Although data regarding these factors could 
improve public health priorities worldwide, the impact of 
these risk factors on the incidence of CHD in SSA has been 
minimally explored.(45,46)
HERITABLE RISK FACTORS FOR CONGENITAL 
HEART DISEASE
There is a multitude of evidence that supports the role of 
genetics in CHD, including population-based studies, twin 
studies, and the recurrence risk between 2- and 80-fold for 
f irst-degree relatives of CHD patients.(5) Population-based 
studies have revealed an elevated incidence of certain CHD 
subtypes such as septal defects in consanguineous popula-
tions, suggesting a recessive genetic contribution to the devel-
opment of CHD.(39,47,28) Previous studies by Wang, et al.(12) and 
Øyen, et al.(49,50) found an increased risk of recurrence of 
both similar and discordant forms of CHD amongst relatives 
when compared to the general population. The elevated recur-
rent risk in consanguineous populations and relatives, who 
share a genetic background, emphasises the genetic contribu-
tion to CHD pathogenesis. 
CHD is a complex heterogeneous genetic disorder associated 
with both familial and sporadic inheritance patterns (Figure 1). 
Familial CHD mutations can be inherited in an autosomal domi-
nant, autosomal recessive, or X-linked manner, and can manifest 
in a variety of clinical phenotypes.(51) Advances in genetic tech-
nology such as WES and CMAs have led to the identification 
of numerous defective genes implicated in CHD. It has been 













CHD pathogenesis, with many still to be discovered.(9,52) Vari-
ants across the frequency spectrum can affect CHD, from 
common variants with low but cumulative impacts, to rare 
mutations or CNVs with high impact.
For the majority of cases CHD occurs sporadically, with only 
2% of CHD cases exhibiting familial disease.(50) Sporadic CHD 
may arise as a result of de novo genetic events, which include 
single-gene mutations, point mutations such as SNVs, chromo-
somal aberrations, and smaller CNVs of particular chromo-
somal regions. It is important to note that CHD is usually 
oligogenic or complex in its genetics and can result from a 
combination of these genetic factors.(5,53,54)
SINGLE GENE MUTATIONS ASSOCIATED WITH 
CONGENITAL HEART DISEASE
Traditional genetic techniques such as linkage analysis and 
candidate gene approaches have enabled the discovery of 
numerous causative genes implicated in CHD pathogenesis. 
However, these techniques rely on multiple affected family 
members and an understanding of the underlying molecular 
pathways of cardiac development, which may be challenging in 
CHD. Previous studies have identified rare causal mutations in 
genes encoding cardiac transcription factors such as NKX2-5, 
GATA4, and TBX5 in patients with non-syndromic CHD.(55-57) 
These transcription factors control critical events during car-
diac development and regulate genes important for cardio-
myocyte differentiation, proliferation, and apoptosis.(55,58) Addi-
tionally, genes that encode structural proteins including cardiac 
actins and myosins have been linked to CHD.  
CHD has been attributed to Mendelian syndromes in 3% - 5% 
of cases.(40) For example, truncating mutations in the T-box 
transcription factor, TBX5, have been linked to Holt-Oram 
syndrome, a Mendelian disease often associated with cardiac 
abnormalities.(36) Haploinsufficiency of the transcription factor 
TBX1 is a common finding in individuals with DiGeorge syn-
drome and is responsible for many of the associated cardio-
vascular phenotypes.(59) The NOTCH signalling pathway gene 
NOTCH1 has been identified as a major susceptibility gene 
for defects such as bicuspid aortic valve, aortic stenosis, and 
TOF.(10,60) Mutations in the NOTCH1 ligand JAG1, and 
NOTCH2 have been associated with Alagille syndrome, an 
autosomal dominant disorder linked to CHD.(61) The complex 
nature of CHD genetics, in which one gene can give rise to 
more than one type of CHD, and one CHD can be caused 
by mutations in more than one gene, has made establishing 
phenotype-genotype correlations a major challenge.(49)
CHROMOSOMAL ABNORMALITIES 
ASSOCIATED WITH CONGENITAL 
HEART DISEASE
A chromosomal abnormality occurs when chromosomal mate-
rial is lost or gained and can cause a range of genetic disorders 
if dosage-sensitive genes are affected.(40) Chromosomal abnor-
malities contribute to approximately 8% - 20% of CHD 
cases.(9,53) The chromosomal causes of CHD can be divided into 
2 categories: gross chromosomal anomalies (or aneuploidies), 
and smaller CNVs (Figure 2).(40)
FIGURE 1: Typical inheritance patterns in CHD. 
A. Complex inheritance, in which CHD is infl uenced by genetic 
factors, as well as environmental and epigenetic factors. 
B. De novo inheritance, in which sporadic mutations (or chromo-
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ANEUPLOIDIES
Aneuploidy is typically defined as an abnormal number of chro-
mosomes.(8) Chromosomal aneuploidies were the first genetic 
causes of CHD to be discovered and continue to play an 
important role in CHD pathology today.(5,44) The most com-
mon aneuploidy is Trisomy 21 (T21 or Down syndrome). This 
genetic syndrome affects approximately 1 in 800 individuals 
and is the most common chromosomal disorder seen in indi-
viduals with CHD.(8) Cardiac complications are the most com-
mon cause of death amongst T21 syndrome patients,(62) and 
approximately 40% - 50% of individuals with T21 syndrome 
have an associated cardiac defect. T21 syndrome patients com-
monly present with an atrial septal defect (ASD), ventricular 
septal defect (VSD), PDA, atrioventricular septal defect, or 
TOF.(8) Turner syndrome (TS) results as a partial or complete 
loss of the X chromosome in females,(54) and 33% of cases 
occur in conjunction with CHD, usually on the left side of the 
heart.(5) Bicuspid aortic valve is the most common heart defect 
associated with TS, with a prevalence of 15% - 30%, followed 
by coarctation of the aorta which has a prevalence of 7% - 18%. 
These cardiac anomalies can lead to serious complications 
for individuals with TS, including aortic dilation and dissec-
tion.(63) CHD is observed in 60% - 80% of individuals with 
trisomy 13 (Patau syndrome) and trisomy 18 (Edwards syn-
drome).(5) Another common aneuploidy is Klinefelter syndrome. 
Approximately 50% of males born with Klinefelter syndrome 
have an associated CHD, usually presenting with PDA or an 
ASD.(54) A selection of well-established chromosomal abnor-
malities associated with CHD is shown in Table II.
COPY NUMBER VARIATION
Copy number variation is a type of structural genetic variation 
whereby segments of the genome are duplicated or deleted. 
CNVs are a subgroup of structural variants comprising inser-
tions, deletions and complex rearrangements of any size. In this 
review, CNVs are defined as microdeletions/microduplica-
tions of the genome that are larger than 1 kilobase (kb) in size 
and affect the dosage of one or more genes. CNVs typically 
arise from nonallelic homologous recombination (NAHR) during 
meiosis (Figure 3),(64) although other mechanisms responsible 
for CNV generation include non-homologous end-joining, fork 
stalling, template switching, and L1-mediated retro-transposi-
tion; these are discussed in detail elsewhere.(64,65)
Genomic microduplications and microdeletions can range in 
size from 1 kb to several mega-bases and are a common source 
FIGURE 2: Chromosomal causes of CHD. 
Representation of typical chromosomal alterations. Chromosomes are depicted in light orange, and regions of deletion or duplication are in 
dark orange (Illustration by Nicole A. Saacks).
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of genetic variation associated with many Mendelian diseases 
and genetic disorders.(66) Emerging evidence has indicated 
that CNVs are important contributors to numerous disorders 
including cancer,(67) neuropsychiatric disorders,(68) neuro-
developmental disorders,(69) and congenital defects including 
CHD.(41) CNV mutations can be inherited or de novo and can 
lead to altered copies of dosage-sensitive genes, the effects of 
which range from benign to fatal depending on the function of 
the genes implicated.(70) Large CNVs comprising several million 
base pairs can be detected by cytogenetic analyses and/or 
fluorescence in situ hybridisation (FISH), whereas smaller CNVs 
are identified using high-resolution microarrays that can detect 
single nucleotide polymorphisms and CNVs.(44)
CNVs occur frequently amongst healthy individuals, making up 
about 12% of the genome of the average person.(71) Although 
the majority of CNVs have no phenotypic consequence in 
healthy individuals, microduplications and/or microdeletions 
that implicate dosage-sensitive genes can be detrimental. If 
critical genetic regulatory elements are disrupted, dependent 
genes may be over- or under-expressed which can significantly 
contribute to disease pathogenesis.(21) It is therefore important 
TABLE II: Chromosomal abnormalities associated with congenital heart disease.*
Chromosomal anomaly Locus Most common CHD
Chromosomal aneuploidies
Trisomy 8 mosaicism Chromosome 8 VSD, PDA, CoA, TAPVR, TrA
Trisomy 9 mosaicism Chromosome 9 PDA, LSVC, VSD, TOF, pulmonary atresia, DORV
Patau syndrome Chromosome 13 (Trisomy 13) ASD, VSD, PDA, HLHS
Edwards syndrome Chromosome 18 (Trisomy 18) ASD, VSD, PDA, TOF, DORV, TGA, CoA, BAV
Down syndrome Chromosome 21 (Trisomy 21) AVSD, ASD, VSD, TOF, TGA
Turner syndrome  Chromosome X (Monosomy X) CoA, BAV, AS, HLHS
Klinefelter syndrome Chromosome X (47- XXY) MVP, PDA, ASD
Copy number variants
1p36 deletion 1p36 PDA, VSD, ASD, BAV, Ebstein anomaly
1q21.1 microduplication 1q21.1 TOF, TGA, ASD, pulmonary atresia
1q41q42 microdeletion 1q41q42 BAV, ASD, VSD, TGA
1q43q44 microdeletion 1q43q44 VSD, CoA, HLHS
2q31.1 microdeletion 2q31.1 VSD, ASD, PDA
2q37 microdeletion 2q37 VSD, ASD, CoA
Wolf-Hirschhorn syndrome 4p ASD, VSD, PDA, aortic atresia, dextrocardia, TA, TOF
Cri-du-chat syndrome 5p VSD, ASD, PDA
Williams-Beuren syndrome 7q11.23 deletion AS and PS, PPS
8p23.1 deletion 8p23.1 AVSD, PS, VSD, TOF
Kleefstra syndrome 9q34.3 deletion ASD, VSD, TOF, PA stenosis
Jacobsen syndrome 11q deletion HLHS, AS, VSD, CoA
15q11.2 microdeletion 15q11.2 TOF, BAV
15q24 microdeletion 15q24 PDA, PA stenosis, PS
16p11.2p12.2 microdeletion 16p11.2p12.2 TOF, BAV, pulmonary atresia
17q21 microdeletion 17q21 PS, ASD, VSD, BAV
Alagille syndrome 20p12 deletion Peripheral PA hypoplasia, TOF, PS
22q11.2 deletion 22q11.2 IAA type B, TrA, TOF
22q11.2 duplication 22q11.2 TOF, HLHS, VSD, PS, TrA
Phelan-McDermid syndrome 22q13 microdeletion PDA, VSD, ASD, TAPVR
*Adapted from Blue, et al.,(40) Pierpont, et al.,(8) and Soemedi, et al.(11)
AS = aortic stenosis, ASD = atrial septal defect, AVSD =  atrioventricular septal defect, BAV =  bicuspid aortic valve, CoA = coarctation of the aorta, DORV = double-outlet right 
ventricle, HLHS = hypoplastic left heart syndrome, IAA type B = interrupted aortic arch type B, LSCV = persistent left superior vena cava, MVP = mitral valve prolapse, PA = pulmonary 
artery, PDA = patent ductus arteriosus, PPS = peripheral pulmonary stenosis, PS = pulmonary valve stenosis, TA = tricuspid atresia, TAPVR = total anomalous pulmonary venous 
return, TGA = transposition of the great arteries, TOF =  tetralogy of Fallot, TrA - truncus arteriosus, VSD = ventricular septal defect.
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to differentiate pathogenic CNVs from likely benign CNVs 
that are commonly found in the general population.
In the context of CHD, researchers and clinicians have defined 
CNV pathogenicity according to the following criteria: a CNV 
overlapping a known disease-associated region or known 
dosage-sensitive CHD gene; a CNV located in a gene-rich 
region; a CNV that comprises a large deletion or duplication; a 
de novo mutation or a CNV associated with a specific pheno-
type within a family and/or a rare CNV found in less than 1% 
of healthy individuals.(72) CNVs are categorised as variants of 
uncertain clinical signif icance when insuff icient evidence of 
pathogenicity is available at the time of reporting. 
The discovery of pathogenic and potentially pathogenic CNVs 
associated with CHD has significantly improved our under-
standing of the aetiology of the disease.(8) Investigation of the 
role of CNVs in CHD pathology has led to the identification of 
numerous dosage-sensitive genes that are critical for cardiac 
development. Previous studies of large CHD cohorts have 
detected a1.8-fold to 3.9-fold greater burden of CNVs in 
CHD cases compared to controls, with large, rare, gene-con-
taining CNVs having a greater impact on CHD.(11,21,41,68)
COPY NUMBER VARIATION IN SYNDROMIC 
CONGENITAL HEART DISEASE
Cardiac defects commonly occur in conjunction with a multi-
tude of genetic disorders (syndromic CHD) characterised by 
large CNVs (Table II). The most common microdeletion in 
humans is 22q11.2 deletion syndrome, caused by a deletion 
that is not visible by standard karyotyping on the long (q) arm 
of chromosome 22 as a result of NAHR.(5) The cardiac phen-
otype for 22q11.2 deletion syndrome varies but usually pre-
sents with TOF, truncus arteriosus, and/or interrupted aortic 
arch- type B.(15) It appears that deletion of TBX1 is the primary 
causal mechanism to the clinical phenotype associated with the 
syndrome.(73) Additional well-characterised CHD-associated 
CNVs include a deletion at 7q11.23, which causes Williams-
Beuren syndrome,(51) a deletion at 11q24-25, which results in 
FIGURE 3: Nonallelic homologous recombination.
NAHR is a form of recombination between 2 DNA regions with high sequence similarity, and 1 of the major mechanisms underlying CNV 
formation. This unequal crossing over results in reciprocal deletion and duplication of the intervening sequence. If this occurs during meiosis, 































Jacobsen Syndrome,(74) a deletion at 8p23, which leads to 
haploinsuff iciency of GATA4, resulting in a variety of CHD 
phenotypes with neurodevelopmental delay,(75) and a 1p36 
deletion, which commonly occurs in conjunction with a septal 
defect, and is associated with orofacial malformations, micro-
cephaly, and mental retardation.(51) The majority of these ge-
netic disorders cannot be identif ied by conventional kary-
otyping and require CMA or FISH for an accurate diagnosis.(21)
COPY NUMBER VARIATION IN NON-
SYNDROMIC CONGENITAL HEART DISEASE
Non-syndromic CHD can occur in isolation or in conjunction 
with ECAs such as neurodevelopmental delay and/or dys-
morphism. Several studies have demonstrated that CNV is a 
significant contributory factor to the development of CHD 
with ECAs. For example, Thienpont, et al.(76) found a rare 
causative CNV in 17% of 60 CHD patients, including CNVs in 
regions of known cardiac transcription factors (NKX2-5 and 
NOTCH1), suggesting an association between CNV and CHD. 
A similar study by Richards, et al.(77) identified rare CNVs in 
25% of 40 patients with CHD who showed normal karyotypes. 
Half of the cohort presented with isolated CHD and the other 
half had CHD with ECAs. However, causative CNVs were 
only detected in study subjects who presented with CHD and 
ECAs. Syrmou, et al.(78) detected CNVs in 37 of 55 individuals 
with CHD (67%); 81% of the CNV-positive CHD patients 
presented with ECAs. Collectively, these studies demonstrate 
the important role of CNVs in the development of CHD with 
ECAs, and that the genes implicated in CHD tend to have 
multiple phenotypic effects. These studies also indicate that 
CMAs can be a useful tool to identify causative CNVs in indi-
viduals presenting with CHD and ECAs when the standard 
karyotype appears normal.(77)
Most CHD cases (up to 85%) occur in isolation without ECAs. 
However, the role of CNVs in isolated CHD has been mini-
mally explored. Identifying isolated CHD is often challenging, as 
ECAs can be easily missed, or not yet present at the time of 
diagnosis, especially in very young study populations. Longi-
tudinal studies with carefully phenotyped study subjects are 
required to define the role of CNV in isolated CHD.(21) Previous 
large-scale studies have investigated CNVs in cohorts which 
include patients with isolated CHD and patients with CHD and 
ECAs. Soemedi, et al.(79) found that a duplication of the gap-
junction gene GJA5 increased the risk of TOF by ten-fold. This 
study also showed that microdeletions of the 1q21.1 region 
corresponded to a population-attributable risk of approxi-
mately 1% for TOF. Furthermore, a large-scale genome-wide 
investigation of CNV data from 2 256 individuals with CHD, 
283 trio CHD-affected families, and 1 538 controls was per-
formed by Soemedi, et al. (11) This study showed that rare dele-
tions account for 3% - 4% of the population attributable risk 
for TOF and other CHDs.(11) Tomita-Mitchell, et al.(41) explored 
the effect of CNVs in 945 individuals diagnosed with CHD and 
detected pathogenic CNVs in 4.3% of their study subjects 
(excluding 135 patients with syndromic CHD-associated chro-
mosomal abnormalities). Additionally, Erdogan, et al.(80) identi-
fied de novo causative CNVs in 3% of 105 patients with isolated 
CHD presenting with varied phenotypes. Many of the identified 
CNVs contained genes important for cardiac development, 
and/or genes critical for correct left-right patterning of the heart 
according to animal models. A recent study by Kim, et al.(81) 
identified large pathogenic CNVs (>300kb) that were signi-
ficantly associated with increased postoperative mortality in 
non-syndromic CHD patients.
Overall, these studies highlight the significant impact of CNV 
in CHD pathology and indicate that as genetic testing pro-
gresses, investigating and identifying pathogenic CNVs asso-
ciated with specific forms of CHD will become an increasingly 
useful tool in gene discovery and accurate CHD diagnosis. This 
is particularly important for patients with complex CHD and 
CHD with ECAs, whereby identifying additional anomalies 
not easily detected by standard karyotyping could significantly 
improve disease prognosis and patient outcome. Further-
more, exploring the role of CNVs in CHD will contribute to 
our understanding of healthy cardiac development and related 
perturbations, and provide knowledge relevant to clinical prac-
tice and potential therapeutic strategies.(82)
DISCOVERING GENES FOR CONGENITAL 
HEART DISEASE 
Over the years, many genes involved in cardiac development 
have been discovered. However, the complete process of car-
diogenesis is not fully understood.(52) Emerging sophisticated, 
high-throughput genetic technology such as next-generation 
sequencing has rapidly advanced the pace at which genes are 
being discovered. Next-generation sequencing technologies 
include gene panel tests, whole-genome sequencing, and WES. 
WES is a genomic technique that sequences all the protein-
coding regions of the genome and has been used to identify 
rare, causative SNVs in CHD-associated genes as well as pre-
viously unreported genes, in both small and large patient 
cohorts. For example, Page, et al.(10) used WES to detect unique 
pathogenic variants in a cohort of 829 non-syndromic TOF 
patients. Similarly, a study by Zaidi, et al.(83) performed WES on 
362 sporadic severe CHD patients, their parents, and 264 
control trios and found a significant excess of de novo damaging 
mutations in genes involved in cardiac development amongst 
the patients. 
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In the past, detection of aneuploidies and gross chromosomal 
aberrations has relied heavily on standard karyotyping. How-
ever, smaller CNVs are not easily detected by this method and 
require a higher resolution CMA analysis (Figure 4). CMA is a 
clinical genetic technique that includes single nucleotide poly-
morphism (SNP) arrays or comparative genomic hybridisation 
(CGH) and allows for the interrogation of rare CNVs known 
to be associated with a disease, as well as other emerging 
chromosomal deletions and duplications in the genome not 
visible by standard karyotyping.(84) Although the resolution of 
CMAs depends on many factors, array CGH and SNP arrays 
are usually able to detect CNVs upwards of 50 - 100kb in size 
(Figure 4). It is likely that 5% - 15% of nonsyndromic CHD is 
attributable to CNVs above 100kb, although the contribution 
of CNVs smaller than 50kb is unclear due to the limited resolu-
tion of these techniques (Figure 4). Sequencing technologies 
such as WES are only able to detect insertions or deletions less 
than 100bp in size, but the role of CNVs between 100bp and 
50kb may be delineated using long-read sequencing, which has 
not been utilised in CHD studies as yet. Nevertheless, CMA is 
becoming an increasingly important tool used in both prenatal 
and postnatal clinical genetic settings,(84) and has led to the 
identification of numerous pathogenic CNVs implicated in 
CHD discussed elsewhere.(41,76,77,79,80) The International Standard 
Cytogenomic Array Consortium recommends CMA as the 
first-tier cytogenetic diagnostic test for children born with con-
genital abnormalities including CHD, as it provides the most 
comprehensive coverage of the genome.(85)
GENETICS OF CONGENITAL HEART DISEASE 
IN SUB-SAHARAN AFRICA
CHD has been described as a “neglected” condition in South 
Africa, with an underestimated reported prevalence of 
approximately 2.35 per 1 000 live births.(3) In 2013, Zühlke, 
Mirabel, & Marijon provided evidence that suggested the 
burden of CHD is vastly underestimated as a result of poor 
prognoses for African children born with CHD.(26) There is a 
lack of African-based evidence on the genetic basis of cardio-
vascular disease in SSA due to poor funding and limited local 
expertise.(86) Consequently, the major genetic breakthroughs 
for CHD that have been seen in high-income countries of the 
world over the past few decades, have not been replicated in 
most LMICs including South Africa. 
The epidemiology of CHD in Africa shows a spectrum of CHD 
phenotypes with varied prevalence.(86) However, there are 
relatively few genomic studies in SSA CHD populations; these 
studies could contribute to our understanding of the epi-
demiological data, and how we manage and treat African 
children with CHD.(86) A comprehensive review of the available 
literature on the genetics of CHD in SSA revealed 4 indepen-
dent studies that used molecular genetic approaches to inves-
tigate the causes of CHD in African populations.(87-90) A genomic 
study in Rwanda was done in 2014 where echocardiography, 
standard karyotyping, and Multiplex Ligation-dependent Probe 
Amplification (MLPA) was performed on 125 patients with 
clinical features of genetic disorders. The study showed that 64 
of the 125 study subjects had CHD, and a genetic cause was 
FIGURE 4: Comparison of different CNV detection methods.
Indicated are the sizes of CNVs that are detectable by each genetic technique. Karyotyping is limited to the detection of whole and partial 
chromosomal aneuploidy, while FISH, array CGH and SNP array can be used to detect smaller CNVs. Sequencing technologies such as whole-
exome sequencing and whole-genome sequencing can only detect small insertions or deletions (approximately 100 bp).   
CGH = comparative genomic hybridisation, CNV = copy number variation, FISH = fl uorescence in situ hybridisation, kb = kilobase, 
























found for 61 of the 64 subjects, although this high detection 
rate may have been influenced by the selection of participants 
with signs of genetic syndromes. Of the 22 patients who pre-
sented with normal karyotypes, MLPA, and FISH analyses 
enabled Teteli and colleagues to detect a 7q11.23 duplication, 
a 13qter deletion, and a 22q11.2 deletion within the study 
cohort.(88) Two years later, De Decker, et al.(87) used FISH to 
determine the prevalence of 22q11.2 deletion syndrome in 
children with CHD at Red Cross War Memorial Children’s 
Hospital in Cape Town. This genetic study identified deletions 
at the 22q11.2 locus in six out of 125 patients (4.8%). Similarly, 
Wonkam, et al.(89) investigated the prevalence of 22q11.2 
deletion syndrome in CHD patients in Cameroon using MLPA 
and FISH. In this study, 22q11.2 deletion was detected in 2 of 
70 patients (2.8%). Both patients had conotruncal heart defects 
in conjunction with ECAs.(89) Most recently, a WES study of 
98 Nigerian CHD patients found disease-causing mutations in 
known CHD genes in 9% of the patient cohort, with 77.8% of 
the mutation-positive patients presenting with syndromic 
disease.(90) Collectively these studies illustrate the ability to 
diagnose syndromic CHD using standard karyotyping and FISH, 
and their relevance in genomic studies on the African content. 
However, except for the Nigerian WES study, these CHD 
investigations focussed mainly on individuals with known ge-
netic disorders which contribute to a small fraction of the total 
burden of CHD. 
To our knowledge, there has been minimal research into the 
genetic basis of non-syndromic CHD in Africa and imple-
menting techniques that can identify potential causative single-
gene mutations and CNVs in genes involved in cardiac develop-
ment is becoming increasingly important. Advanced genetic 
platforms including next-generation technologies (whole-
genome sequencing and WES) and high-resolution CMA allow 
for the interrogation of entire genomes and CNVs of all sizes 
in a single run.(86) Access to clinical genetic testing in Africa 
remains extremely limited. Although large-scale initiatives such 
as the Human, Hereditary and Health in Africa (H3Africa) con-
sortium seek to address the lack of genomic information from 
African populations and build capacity for research in the 
region,(91) translating genomic information to the clinical setting 
is a challenge. Issues include access to and cost of sequencing or 
genotyping arrays, limited knowledge of the role of genetics in 
healthcare, and the dearth of experts and genetic counsellors 
across Africa.(92,93) We are not aware of any genomic centres of 
excellence in Africa. However, using these genomic platforms 
to investigate the genetic underpinnings of CHD in Africa will 
provide valuable insight into the complexities of CHD, by vali-
dating the disease-causing genes found in other populations, 
refining disease-associated loci, and possibly identifying new 
genes that may contribute to CHD pathogenesis. 
CONCLUSION
Many large-scale genetics studies have demonstrated the con-
tribution of CNVs and single nucleotide variants to the devel-
opment of cardiac defects in individuals of European ancestry. 
While this approach has identified numerous pathogenic and 
likely pathogenic variants linked to CHD, to our knowledge, 
no study to date has investigated the contribution of rare 
CNVs to the development of CHD in African populations 
including South Africa. Improving our understanding of the 
genetic architecture and risk factors associated with CHD in 
patients of African descent is the first step toward improving 
the accuracy of CHD diagnosis, and a crucial step toward 
identifying potential measures to combat CVD. Moreover, 
exploring the genetics of CHD has the potential to improve 
the quality of life for children born with CHD in Africa, and will 
enable clinicians to identify familial inheritance patterns and 
predict recurrence risks and prognostic outcomes pre- and 
post-surgical intervention.
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